Pharmaceutical Research

AusCann is committed to a pharmaceutical development program underpinned by rigorous research. In-house capability is augmented by our network of specialist expertise and infrastructure. Our focus is on developing reliable, stable and standardised cannabinoid-based therapeutics.

Clinical Research

Sponsored Clinical Trials

Investigational Product Trial Title Status Study ID
Neuvis® Platform:
Powder in hard-shell capsule
ACNV201: 2.5 mg: 2.5 mg THC:CBD
ACNV202: 10 mg: 10 mg THC:CBD
A Randomised, Open-label, Cross-over Study to Evaluate the Pharmacokinetics of a Single Dose of two Formulations of Orally Administered Tetrahydrocannabinol/Cannabidiol Combination in Fed Healthy Volunteer Recruitment Complete ACTRN12620000462987

Investigator Initiated Studies

Investigator-initiated studies (IIS) play a pivotal role in exploring the clinical application of pharmaceutical products. These studies are initiated and managed by research teams outside of the pharmaceutical industry, who take the responsibility for being trial sponsor as well as institution and investigator, under the relevant regulations, guidelines and codes of conduct.

AusCann accepts expressions of interest from researchers wishing to conduct relevant, quality studies for the generation of clinical evidence associated with AusCann’s products, and may support researchers with drug supply, funding and/or information, as permitted under regulations and where aligned with areas of strategic focus for the company. Potential Support consists of:




Drug supply





Real-world Clinical Data

AusCann is rolling out an advanced data management and analytics platform for the collection of real-world data (RWD). The company is customising the platform to meet the needs of Australian medicinal cannabis prescribers. The key specifications for the platform have been defined upon advice from key opinion leaders in the clinical fields of pain, palliative care and geriatrics.

The platform is being piloted with clinicians prescribing AusCann’s medicines, to assist in evaluating clinical outcomes for individual patients and assessing clinical impact across patient cohorts.

If you are a health care professional and would like to know more regarding the real-world clinical data platform and register your interest in participating in the pilot, please contact